Anthropic Acquires Biotech Startup Coefficient Bio for $400 Million

Anthropic has acquired Coefficient Bio, a stealth AI biotech startup, in a stock deal valued at approximately $400 million. The news broke on April 3, 2026, marking a clear strategic shift for the AI lab.

Coefficient Bio was founded just eight months before the acquisition by Nathan Frey and Samuel Stanton, both former members of Genentech's Prescient Design computational drug discovery unit. Despite having fewer than ten employees, the company had developed an AI platform specifically for biological research and drug discovery, with the ambitious goal of pursuing artificial superintelligence for science.

The team will now join Anthropic's healthcare and life sciences division, led by Eric Kauderer-Abrams. The move signals a shift beyond adapting the general-purpose Claude model for scientific workflows, toward building biology-specific AI models from the ground up.

The acquisition price represents roughly 0.1% dilution against Anthropic's $380 billion post-money valuation from its February Series G funding round.

For enterprise technology leaders, this signals that the major AI labs are now moving into specialized industry domains with purpose-built models rather than general-purpose solutions, a trend that is likely to accelerate throughout 2026.